Skip to main content

Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Rise Above Previous 52-Week High

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) traded today at a new 52-week high of $152.56. This new high was reached on below average trading volume as 227,000 shares traded hands, while the average 30-day volume is approximately 738,000 shares.

Over the past year, Biohaven Pharmaceutical Holding Company Ltd. has traded in a range of $77.10 to $152.56 and is now at $152.12, 97% above that low.

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is currently priced 12.0% above its average consensus analyst price target of $133.93.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.